Case Report

Community-acquired methicillin-resistant *Staphylococcus aureus* pyomyositis in an intravenous drug user

A. Fowler and A. Mackay

Department of Microbiology, Queen Elizabeth Hospital, Woolwich, London SE18 4QH, UK

Pyomyositis is a disease of abscess formation deep within large striated muscles. Outside of the tropics it is a rare disease which occurs mainly in certain patient populations such as the immunosuppressed or intravenous drug users (IDUs). A case of community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) pyomyositis in an IDU is described.

The incidence of both CA-MRSA and pyomyositis is currently increasing. To the authors’ knowledge this is the first reported case of CA-MRSA pyomyositis in the UK. Cases of CA-MRSA pyomyositis are likely to increase and it may be necessary to empirically treat certain patients with glycopeptides.

**Introduction**

Pyomyositis was first described in the tropics and is often called tropical pyomyositis. It is an abscess-forming infection of skeletal muscle (Ebright & Pieper, 2002). It is a rare disease and was only recognized as a temperate condition as recently as 1971 (Levin et al., 1971). The disease is characterized by cramping pains, followed by oedema, worsening discomfort and mild fever. The muscle may be indurated with oedema and tenderness increasing as the infection progresses. Obvious fluctuance develops in about half the patients. As the infection progresses the patient may become increasingly systemically unwell with septicemia. The abscesses may develop via spread from a haematogenous route or from contiguous soft tissue or bone. The most common sites of abscess formation are the quadriceps, gluteus, shoulder and upper arm muscles. Multiple foci occur in about 40 % of patients. It is caused in 75 % of cases by *Staphylococcus aureus* (Bickels et al., 2002). A review of the literature, using searches by Medline and EMBASE, demonstrated that MRSA is an infrequent cause of the infection with the first ever case report in 1996 (Kong et al., 1996).

**Case report**

A 21-year-old Caucasian woman presented with a 2-week history of pain and swelling in the right thigh. There was no history of trauma or immobilization. She gave a history of intravenous drug use, sometimes injecting into her groin. She had no other relevant past medical history and no previous hospital admissions. On examination she was apyrexial with a tachycardia of 100 b.p.m., a blood pressure of 99/60 mmHg and her thigh was swollen, tender and warm. Laboratory results showed: haemoglobin 11.7 g dl⁻¹; white cell count 24.3 x 10⁹ l⁻¹; neutrophils 22.9 x 10⁹ l⁻¹; platelets 682 x 10⁹ l⁻¹; d-dimer positive; urea 20.0 mmol l⁻¹; creatinine 112 μmol l⁻¹. A clinical diagnosis of deep vein thrombosis (DVT) with superadded cellulitis was made. She was admitted for intravenous hydration, anticoagulant therapy and oral antimicrobial treatment with flucloxacillin (500 mg q.d.s.). She was subsequently switched to intravenous flucloxacillin (1 g q.d.s.), and benzylpenicillin (1-2 g q.d.s.) was added to the antibiotic treatment regimen.

The patient then deteriorated with worsening pain and swelling of the thigh and groin. She became pyrexial (39°C), increasingly tachycardic (128 b.p.m.) and hypotensive (70/40 mmHg). The white cell count had risen to 46 x 10⁹ l⁻¹ (neutrophils 40 x 10⁹ l⁻¹). Imaging with ultrasound ruled out a DVT but computed tomography (CT) revealed grossly swollen iliopsoas and upper thigh muscles and possible muscle necrosis. Magnetic resonance imaging (MRI) showed grossly swollen, high signal upper thigh muscles with abscess formation. Flucloxacillin was subsequently switched to meropenem (1 g b.d.) and the dose of benzylpenicillin was increased (2.4 g q.d.s.). A single dose of gentamicin (120 mg) was also administered.

Forty-eight hours after admission the patient underwent extensive surgical debridement of the right quadriceps muscles. The patient was subsequently admitted to the intensive care unit (ICU). Gram-positive cocci and numerous white cells were seen on microscopy of the necrotic material excised at operation. Sodium fusidate was added to the antibiotic regimen (500 mg t.d.s.). The necrotic material

**Abbreviations:** CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*; DVT, deep vein thrombosis; ICU, intensive care unit; IDU, intravenous drug user.
was processed by inoculating the sample onto several agar plates including horse blood agar (HBA; CM0271, Oxoid); MacConkey agar (CM0007; Oxoid); chocolate agar incubated in 5% CO₂ at 37°C; HBA with colistin and nalidixic acid incubated in air; Columbia blood agar (CBA; CM0331, Oxoid) with and without neomycin aerobically and anaerobically for 2 and 5 days, respectively. Blood culture specimens were processed using the BACTEC 9240 system (Becton Dickinson Microbiology). The cultures were sterile after 5 days of routine incubation in this system.

The culture from necrotic tissue yielded a moderate growth of Gram-positive cocci. MRSA and Streptococcus pyogenes were identified using slide coagulase and tube coagulase systems and the API 20 Strep (bioMérieux) method of identification. Antibiotic sensitivity was tested on Iso-Sensitest agar (ISA; CM0471, Oxoid) with and without neomycin aerobically and anaerobically. The cultures were sterile after 5 days of routine incubation in this system. Antibiotic sensitivity was tested on Iso-Sensitest agar (ISA; CM0471, Oxoid) with and without neomycin aerobically and anaerobically. The cultures were sterile after 5 days of routine incubation in this system. Antibiotic sensitivity was tested on Iso-Sensitest agar (ISA; CM0471, Oxoid) with and without neomycin aerobically and anaerobically.

The first case report of MRSA pyomyositis in the literature was in 1996 (Kong et al., 1996). Since then there have only been 12 further cases reported worldwide (Hayashi et al., 2003; Millar et al., 2000; Liew et al., 1998; Milochau et al., 1997; Endoh et al., 2000; Fan et al., 2002; Vassilopoulos et al., 1997; Ruiz et al., 2005) and in 9 of these the MRSA was acquired from the community (Kong et al., 1996; Liew et al., 1998; Milochau et al., 1997; Fan et al., 2002; Vassilopoulos et al., 1997; Ruiz et al., 2005). Most recently, a case series of four patients was reported in the USA (Ruiz et al., 2005). The MRSA was community-acquired, leading the authors to conclude that CA-MRSA is emerging as an important cause of pyomyositis. To our knowledge this is the first case of CA-MRSA pyomyositis to be reported in the UK.

Despite being a rare disease, the incidence of pyomyositis is increasing in Western countries of the world (Hsueh et al., 1996; Skoutelis et al., 1993). There is an association between intravenous drug use and pyomyositis (Ebright & Pieper, 2002). This is thought to be due to impaired cellular and humoral immunity and abnormal skin bacterial colonization along with the repeated introduction of nonsterile fluids (Hsueh et al., 1996). Other at-risk populations include patients with HIV, diabetes mellitus and malignancy. A rising number of such patients will result in a greater number of cases of pyomyositis in the future (Harbarth & Lew, 1997).

Infections due to MRSA are increasing within the community (McCarthy, 2003). There is mounting evidence that MRSA is being isolated in patients who have not been hospitalized and that it may also arise de novo (Salmenlinna et al., 2002), with reports of infection with MRSA in adults and children without known risk factors (Charlebois et al., 2002). Although healthy persons are at low risk of colonization, IDUs are thought to be at risk. An outbreak of a single clone of MRSA has been described in Zurich among IDUs (Fleisch et al., 2001) and a large prevalence based study in San Francisco showed that intravenous drug use is a significant risk factor for community colonization of MRSA (Charlebois et al., 2002). In the UK two centres have recently reported cases of groin abscesses and endocarditis in IDUs caused by MRSA from the community (Anon, 2003). We predict, therefore, that there will be an increase in the incidence of CA-MRSA pyomyositis, particularly amongst IDUs.

This potential rise is of concern because pyomyositis is difficult to diagnose and prompt treatment is required to prevent complications. The difficulties and delays in diagnosis arise for several reasons (Harbarth & Lew, 1997). Firstly, the presentation is often vague, particularly if the affected muscle is deeply sited and local signs are not apparent (Bickels et al., 2002); secondly, there is a broad spectrum of clinical presentation; and thirdly, as the infection is so rarely seen in temperate climates, it is less likely to be considered. Other diagnoses (e.g. DVT) will be considered first (Valeriano-Marcet et al., 2003), particularly in an IDU, where DVT is common. Correct therapy may therefore be significantly delayed, a delay which is exaggerated in patients with CA-MRSA pyomyositis being treated with conventional antibiotics. A delay in diagnosis can lead to joint destruction, lung and brain abscesses as well as sepsis and occasionally death (Bickels et al., 2002). In IDUs who receive appropriate treatment, mortality from pyomyositis is quoted as less than 10% (Ebright & Pieper, 2002).

In summary, we report the first case of CA-MRSA pyomyositis in the UK and suggest that the incidence of this disease may increase in the future both here and abroad. We postulate that, in the UK and other countries with an increasing burden of CA-MRSA, it may be necessary to consider including a glycopeptide in the initial treatment of pyomyositis, until cultures grow sensitive organisms, in high-risk patient populations such as IDUs even if the patient is admitted from the community. This option must also be considered if patients are failing to respond to conventional treatment. We acknowledge that this attitude may place even greater selection pressure on the spread of vancomycin-resistant strains of MRSA. We feel, however, that clinicians should carefully consider the use of a glycopeptide antibiotic in the initial treatment of such cases.
because there are such devastating outcomes in patients in whom correct therapy is delayed.

References


